Plasma metabolomics profiling of 580 patients from an Early Detection Research Network prostate cancer cohort.
Journal
Scientific data
ISSN: 2052-4463
Titre abrégé: Sci Data
Pays: England
ID NLM: 101640192
Informations de publication
Date de publication:
25 11 2023
25 11 2023
Historique:
received:
15
03
2023
accepted:
14
11
2023
medline:
27
11
2023
pubmed:
26
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
Prostate cancer is the second most common cancer in men and affects 1 in 9 men in the United States. Early screening for prostate cancer often involves monitoring levels of prostate-specific antigen (PSA) and performing digital rectal exams. However, a prostate biopsy is always required for definitive cancer diagnosis. The Early Detection Research Network (EDRN) is a consortium within the National Cancer Institute aimed at improving screening approaches and early detection of cancers. As part of this effort, the Weill Cornell EDRN Prostate Cancer has collected and biobanked specimens from men undergoing a prostate biopsy between 2008 and 2017. In this report, we describe blood metabolomics measurements for a subset of this population. The dataset includes detailed clinical and prospective records for 580 patients who underwent prostate biopsy, 287 of which were subsequentially diagnosed with prostate cancer, combined with profiling of 1,482 metabolites from plasma samples collected at the time of biopsy. We expect this dataset to provide a valuable resource for scientists investigating prostate cancer metabolism.
Identifiants
pubmed: 38007532
doi: 10.1038/s41597-023-02750-7
pii: 10.1038/s41597-023-02750-7
pmc: PMC10676366
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Dataset
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
830Subventions
Organisme : NCI NIH HHS
ID : R01 CA179100
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA113913
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Prostate. 2013 Oct;73(14):1547-60
pubmed: 23824564
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2454-2462
pubmed: 33093161
Cent European J Urol. 2020;73(2):123-126
pubmed: 32782829
J Cheminform. 2010 Oct 18;2(1):9
pubmed: 20955607
Prostate Int. 2014 Sep;2(3):133-9
pubmed: 25325025
Metabolites. 2019 Mar 08;9(3):
pubmed: 30857149
Anal Chem. 2006 Jul 1;78(13):4281-90
pubmed: 16808434
Sci Transl Med. 2012 Mar 28;4(127):127rv3
pubmed: 22461644
Anal Chem. 2009 Aug 15;81(16):6656-67
pubmed: 19624122
Oncology (Williston Park). 2014 Feb;28(2):135-42
pubmed: 24701701
J Appl Lab Med. 2020 Mar 1;5(2):342-356
pubmed: 32445384
Front Public Health. 2022 Feb 16;10:811044
pubmed: 35252092
World J Urol. 2007 Mar;25(1):3-9
pubmed: 17364211
Urology. 2003 Feb;61(2):365-9
pubmed: 12597949
Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):941-7
pubmed: 9276358
J Natl Compr Canc Netw. 2015 Jan;13(1):61-8
pubmed: 25583770
Int J Mol Sci. 2021 Apr 22;22(9):
pubmed: 33922033
Diagnostics (Basel). 2019 Feb 19;9(1):
pubmed: 30791464
Metabolomics. 2018 Sep 20;14(10):128
pubmed: 30830398
Br J Cancer. 2009 Dec 1;101(11):1833-8
pubmed: 19904272
J Transl Med. 2022 Jun 17;20(1):275
pubmed: 35715864
Bioinformatics. 2022 Jan 27;38(4):1168-1170
pubmed: 34694386
Sci Data. 2023 Nov 25;10(1):830
pubmed: 38007532